作者
Kévin Chevalier,Benjamin Thoreau,Marc Michel,Bertrand Godeau,C. Agard,Thomas Papo,Karim Sacré,Raphaèle Séror,Xavier Mariette,P. Cacoub,Y. Benhamou,H. Lévesque,Cécile Goujard,Olivier Lambotte,Bernard Bonnotte,M. Samson,Félix Ackermann,Jean M. Schmidt,P. Duhaut,Jean‐Emmanuel Kahn,Thomas Hanslik,N. Costedoat‐Chalumeau,Benjamin Terrier,Alexis Régent,Bertrand Dunogué,Pascal Cohen,Véronique Le Guern,Eric Hachulla,Benjamin Chaigne,Luc Mouthon
摘要
Abstract Objectives The objective of this study is to better characterize the features and outcomes of a large population of patients with mixed connective tissue disease (MCTD). Methods We performed an observational retrospective multicenter cohort study in France. Patients who fulfilled at least one diagnostic criterion set for MCTD and none of the criteria for other differentiated CTD (dCTD) were included. Results Three hundred and thirty patients (88% females, median [interquartile range] age of 35 years [26–45]) were included. The diagnostic criteria of Sharp or Kasukawa were met by 97.3% and 93.3% of patients, respectively. None met other classification criteria without fulfilling Sharp or Kasukawa criteria. After a median follow‐up of 8 (3–14) years, 149 (45.2%) patients achieved remission, 92 (27.9%) had interstitial lung disease, 25 (7.6%) had pulmonary hypertension, and 18 (5.6%) died. Eighty‐five (25.8%) patients progressed to a dCTD, mainly systemic sclerosis (15.8%) or systemic lupus erythematosus (10.6%). Median duration between diagnosis and progression to a dCTD was 5 (2–11) years. The presence at MCTD diagnosis of an abnormal pattern on nailfold capillaroscopy (odds ratio [OR] = 2.44, 95% confidence interval [95%CI] [1.11–5.58]) and parotid swelling (OR = 3.86, 95%CI [1.31–11.4]) were statistically associated with progression to a dCTD. Patients who did not progress to a dCTD were more likely to achieve remission at the last follow‐up (51.8% vs. 25.9%). Conclusions This study shows that MCTD is a distinct entity that can be classified using either Kasukawa or Sharp criteria, and that only 25.8% of patients progress to a dCTD during follow‐up.